[go: up one dir, main page]

MX2013011098A - Metodos para aumentar la eficacia de la terapia contra el cancer con receptor 1 de folato (folr1). - Google Patents

Metodos para aumentar la eficacia de la terapia contra el cancer con receptor 1 de folato (folr1).

Info

Publication number
MX2013011098A
MX2013011098A MX2013011098A MX2013011098A MX2013011098A MX 2013011098 A MX2013011098 A MX 2013011098A MX 2013011098 A MX2013011098 A MX 2013011098A MX 2013011098 A MX2013011098 A MX 2013011098A MX 2013011098 A MX2013011098 A MX 2013011098A
Authority
MX
Mexico
Prior art keywords
methods
folr1
folate
effectiveness
receiver
Prior art date
Application number
MX2013011098A
Other languages
English (en)
Other versions
MX340640B (es
Inventor
Christina N Carrigan
Kathleen R Whiteman
Gillian Payne
Sharron Ladd
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of MX2013011098A publication Critical patent/MX2013011098A/es
Publication of MX340640B publication Critical patent/MX340640B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G01N33/5759—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oncology (AREA)

Abstract

Se proporcionan los métodos para mejorar el éxito de las terapias contra el cáncer que se dirigen al receptor 1 de folato humano. Adicionalmente se proporcionan kits que comprenden un reactivo útil en los métodos.
MX2013011098A 2011-04-01 2012-03-30 Metodos para aumentar la eficacia de la terapia contra el cancer con receptor 1 de folato (folr1). MX340640B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161471007P 2011-04-01 2011-04-01
PCT/US2012/031544 WO2012135675A2 (en) 2011-04-01 2012-03-30 Methods for increasing efficacy of folr1 cancer therapy

Publications (2)

Publication Number Publication Date
MX2013011098A true MX2013011098A (es) 2013-12-16
MX340640B MX340640B (es) 2016-07-19

Family

ID=46932392

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2015009802A MX346555B (es) 2011-04-01 2012-03-30 Metodos para aumentar la eficacia de la terapia contra el cancer con receptor 1 de folato (folr1).
MX2013011098A MX340640B (es) 2011-04-01 2012-03-30 Metodos para aumentar la eficacia de la terapia contra el cancer con receptor 1 de folato (folr1).
MX2019010336A MX2019010336A (es) 2011-04-01 2013-09-26 Metodos para aumentar la eficacia de la terapia contra el cancer con receptor 1 de folato (folr1).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015009802A MX346555B (es) 2011-04-01 2012-03-30 Metodos para aumentar la eficacia de la terapia contra el cancer con receptor 1 de folato (folr1).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019010336A MX2019010336A (es) 2011-04-01 2013-09-26 Metodos para aumentar la eficacia de la terapia contra el cancer con receptor 1 de folato (folr1).

Country Status (30)

Country Link
US (5) US8709432B2 (es)
EP (4) EP3636279B1 (es)
JP (7) JP6018621B2 (es)
KR (6) KR20200039843A (es)
CN (3) CN103747802B (es)
AU (4) AU2012236219B2 (es)
BR (1) BR112013025415B1 (es)
CA (2) CA3182262A1 (es)
CY (1) CY1119960T1 (es)
DK (1) DK2694106T3 (es)
EA (2) EA201791843A3 (es)
ES (2) ES2965109T3 (es)
HR (1) HRP20180358T1 (es)
HU (1) HUE036172T2 (es)
IL (5) IL281714B2 (es)
LT (1) LT2694106T (es)
ME (1) ME03025B (es)
MX (3) MX346555B (es)
MY (2) MY186591A (es)
NO (1) NO2893540T3 (es)
PL (1) PL2694106T3 (es)
PT (1) PT2694106T (es)
RS (1) RS56916B1 (es)
SG (2) SG193514A1 (es)
SI (1) SI2694106T1 (es)
SM (1) SMT201800103T1 (es)
TR (1) TR201802659T4 (es)
UA (2) UA125636C2 (es)
WO (1) WO2012135675A2 (es)
ZA (1) ZA202007440B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
EP2662096A1 (en) 2005-08-24 2013-11-13 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
PT2437790T (pt) 2009-06-03 2019-06-04 Immunogen Inc Métodos de conjugação
MY171234A (en) 2010-02-24 2019-10-04 Immunogen Inc Folate receptor 1 antibodies and immunoconjugates and uses thereof
CN107537040A (zh) 2011-03-29 2018-01-05 伊缪诺金公司 通过一步法制备类美登素抗体缀合物
UA125636C2 (uk) * 2011-04-01 2022-05-11 Іммуноджен, Інк. Способи ідентифікації раку, який може реагувати на анти-folr1 антитіло або анти-folr1 імунокон'югат
CA3137438A1 (en) 2012-08-31 2014-03-06 Immunogen, Inc. Diagnostic assays and kits for detection of folate receptor 1
AU2013326881B2 (en) 2012-10-04 2018-08-02 Immunogen, Inc. Use of a PVDF membrane to purify cell-binding agent cytotoxic agent conjugates
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
TWI614266B (zh) * 2012-12-07 2018-02-11 協和醱酵麒麟有限公司 抗ｆｏｌｒ１抗體
CN105102455B (zh) 2012-12-21 2018-05-25 荷商台医(有限合伙)公司 亲水性自消耗连接子及其缀合物
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
SG11201509043RA (en) * 2013-05-14 2015-12-30 Immunogen Inc Anti-folr1 immunoconjugate dosing regimens
IL293871B1 (en) 2013-08-30 2025-10-01 Immunogen Inc Antibodies and assays for the detection of folate receptor 1
RU2696579C2 (ru) 2013-10-08 2019-08-05 Иммьюноджен, Инк. Схемы применения иммуноконъюгата анти-folr1
US20150297744A1 (en) * 2014-03-28 2015-10-22 Immunogen, Inc. Anti-FOLR1 Immunoconjugate Dosing Regimens
SG11201610620UA (en) * 2014-06-20 2017-01-27 Bioalliance Cv Anti-folate receptor aplha (fra) antibody-drug conjugates and methods of using thereof
CN113842468B (zh) 2014-09-02 2025-08-29 伊缪诺金公司 用于配制抗体药物缀合物组合物的方法
JP2017527562A (ja) 2014-09-03 2017-09-21 イミュノジェン・インコーポレーテッド 細胞毒性ベンゾジアゼピン誘導体
EA034138B1 (ru) 2014-09-03 2020-01-09 Иммуноджен, Инк. Цитотоксические бензодиазепиновые производные
HUE051715T2 (hu) 2014-11-20 2021-03-29 Hoffmann La Roche T-sejt-aktiváló bispecifikus antigénkötõ molekulák a FolR1 és CD3 ellen
WO2016079050A1 (en) 2014-11-20 2016-05-26 F. Hoffmann-La Roche Ag Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists
SI3221357T1 (sl) 2014-11-20 2020-09-30 F. Hoffmann-La Roche Ag Pogoste lahke verige in načini uporabe
CN108135902A (zh) * 2015-07-30 2018-06-08 爱科谱迅病理研究公司 用于最优癌症治疗的定量FR-α和GART蛋白质
CN116440279A (zh) * 2015-09-17 2023-07-18 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
ES2970186T3 (es) 2015-11-25 2024-05-27 Immunogen Inc Formulaciones farmacéuticas y métodos de uso de las mismas
ES2880731T3 (es) 2016-01-08 2021-11-25 Altrubio Inc Anticuerpos anti-PSGL-1 tetravalentes y usos de los mismos
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
EP4353319A3 (en) 2016-09-28 2024-06-05 Atossa Therapeutics, Inc. Methods of adoptive cell therapy
AU2018229277B2 (en) 2017-02-28 2025-03-20 Immunogen, Inc. Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof
WO2018195243A1 (en) 2017-04-20 2018-10-25 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and conjugates thereof
IT201700087291A1 (it) * 2017-07-28 2019-01-28 Fondazione St Italiano Tecnologia Metodo di imaging di un campione biologico e relativa sonda
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
EP3732178A1 (en) 2017-12-28 2020-11-04 ImmunoGen, Inc. Benzodiazepine derivatives
CN111954681B (zh) * 2018-03-13 2022-12-06 东莞凡恩世生物医药有限公司 抗叶酸受体1抗体及其用途
JP2022527449A (ja) 2019-03-21 2022-06-02 イミュノジェン・インコーポレーテッド 細胞結合剤－薬物複合体の調製方法
US20230094471A1 (en) 2019-03-29 2023-03-30 Immunogen, Inc. Cytotoxic bis-benzodiazepine derivatives and conjugates thereof with cell-binding agents for inhibiting abnormal cell growth or for treating proliferative diseases
ES2966473T3 (es) 2019-04-26 2024-04-22 Immunogen Inc Derivados de camptotecina
CA3138272A1 (en) 2019-04-29 2020-11-05 Immunogen, Inc. Biparatopic fr-alpha antibodies and immunoconjugates
AU2020287165A1 (en) * 2019-06-06 2022-02-03 Mythic Therapeutics, Inc. Antigen-binding protein constructs and uses thereof
CN111579798A (zh) * 2020-05-29 2020-08-25 深圳市锦欣医疗科技创新中心有限公司 一种评估子宫内膜容受性的试剂盒及其使用方法
KR20230066095A (ko) * 2020-09-12 2023-05-12 메디뮨 리미티드 항-b7h4 항체-약물 접합체 요법에 대한 점수산정 방법
CA3220817A1 (en) * 2021-06-04 2022-12-08 Eric WESTIN Treatment of cancer in patients with soluble fr-alpha
WO2023170216A1 (en) * 2022-03-11 2023-09-14 Astrazeneca Ab A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY
WO2025094146A1 (en) 2023-11-02 2025-05-08 Immunogen Switzerland Gmbh Vasconstrictors for reducing ocular toxicity of antibody-maytansinoid conjugates
US12258396B1 (en) * 2024-02-02 2025-03-25 Medicovestor, Inc. Methods of using immunotherapeutics that bind folate receptor alpha
CN117741149A (zh) * 2024-02-19 2024-03-22 卡秋(江苏)生物科技有限公司 一种用于卵巢癌细胞叶酸受体α的检测试剂盒及其应用
WO2025195447A1 (zh) * 2024-03-22 2025-09-25 北京桦冠生物技术有限公司 结合folr1蛋白的抗体、抗体药物偶联物及其用途

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4563304A (en) 1981-02-27 1986-01-07 Pharmacia Fine Chemicals Ab Pyridine compounds modifying proteins, polypeptides or polysaccharides
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US20040049014A1 (en) 1988-12-28 2004-03-11 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
JPH049249A (ja) 1990-04-27 1992-01-14 Kusuda:Kk 塗型剤吹き付け機
US6916605B1 (en) 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
US6004554A (en) 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US20030148406A1 (en) 1992-03-17 2003-08-07 David John King Multivalent antigen-binding proteins
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
JP2002514895A (ja) 1995-09-28 2002-05-21 アレクション、ファーマスーティカルズ、インコーポレーテッド ブタ細胞相互作用タンパク質
US6596850B1 (en) 1998-01-30 2003-07-22 Ixsys, Incorporated Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
WO2000023082A1 (en) 1998-10-19 2000-04-27 Yeda Research And Development Co. Ltd. Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
IT1307309B1 (it) 1999-12-30 2001-10-30 Enea Ente Nuove Tec Peptidi stabilizzanti, polipeptidi ed anticorpi che li comprendono.
KR100863632B1 (ko) 2000-03-31 2008-10-15 퍼듀 리서치 파운데이션 리간드-면역원 접합체를 사용한 치료 방법
DE10037759A1 (de) 2000-08-03 2002-07-04 Gruenenthal Gmbh Screeningverfahren
JP4279554B2 (ja) 2001-02-19 2009-06-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｔ細胞エピトープの識別方法および低減された免疫原性を有する分子の製造方法
US20030087250A1 (en) 2001-03-14 2003-05-08 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
WO2002087424A2 (en) 2001-05-02 2002-11-07 Purdue Research Foundation Treatment and diagnosis of macrophage mediated disease
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
EP1486566A4 (en) 2002-03-01 2005-10-12 Japan Enviro Chemicals Ltd FOR BINDING TO FEMALE SEXUAL HORMONES, PROTEINS AND METHOD FOR THE PRODUCTION THEREOF
WO2003089475A2 (en) 2002-04-22 2003-10-30 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Antibodies, recombinant antibodies, recombinant antibody fragments and fusions mediated plant disease resistance against fungi
WO2004043989A2 (en) 2002-11-07 2004-05-27 Medarex, Inc. Human monoclonal antibodies to heparanase
EP1481993A1 (en) 2003-05-28 2004-12-01 Xerion Pharmaceuticals AG Modulation of the poliovirus receptor function
US20050255114A1 (en) 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
KR101412271B1 (ko) 2003-05-09 2014-06-25 듀크 유니버시티 Ｃｄ２０-특이적 항체 및 이를 이용한 방법
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
KR101424624B1 (ko) 2003-05-14 2014-07-31 이뮤노젠 아이엔씨 약물 콘쥬게이트 조성물
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
AU2004253953A1 (en) 2003-07-02 2005-01-13 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7622112B2 (en) 2003-12-05 2009-11-24 Jody Berry Anti-SARS monoclonal antibodies
US20050232919A1 (en) 2004-02-12 2005-10-20 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
JP5128273B2 (ja) 2004-04-27 2013-01-23 ガラパゴス・ナムローゼ・フェンノートシャップ 未分化哺乳動物細胞の分化を骨芽細胞へと誘導するための方法、作用物質、及び化合物スクリーニングアッセイ
US7241598B2 (en) 2004-06-29 2007-07-10 The Chinese University Of Hong Kong Frame-shifting PCR for germline immunoglobulin genes retrieval and antibody engineering
JP5173426B2 (ja) 2004-10-25 2013-04-03 メルク・シャープ・エンド・ドーム・コーポレイション 抗ａｄｄｌ抗体およびこの使用
EP1827079A4 (en) 2004-12-21 2012-04-11 Monsanto Technology Llc TRANSGENIC PLANTS WITH ADVANCED AGRONOMIC CHARACTERISTICS
JP2008526205A (ja) 2004-12-31 2008-07-24 ジェネンテック・インコーポレーテッド Ｂｒ３に結合するポリペプチド及びその使用
US7700738B2 (en) 2005-01-27 2010-04-20 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール，インク． Ｇｉｔｒ結合分子およびその使用
US7608413B1 (en) 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
RU2007139912A (ru) * 2005-03-30 2009-05-10 Пердью Рисерч Фаундейшн (Us) Способ прогнозирования течения рака на основе количественного анализа клеточного рецептора витамина фолата
EP1879922A2 (en) 2005-04-22 2008-01-23 Morphotek, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
US7786266B2 (en) 2005-05-12 2010-08-31 Oncotherapy Science, Inc. Methods for damaging cells using effector function of anti-DSC2 antibody
CA2606576A1 (en) 2005-05-20 2006-11-23 Lonza Biologics Plc. High-level expression of recombinant antibody in a mammalian host cell
KR20080039844A (ko) 2005-05-24 2008-05-07 아베스타 겐그레인 테크놀로지스 피브이티 리미티드 Ｂ―세포 림프종 치료를 위한 ｃｄ20에 대한 모노클로날항체의 제조 방법
WO2007006041A2 (en) 2005-07-05 2007-01-11 Purdue Research Foundation Imaging and therapeutic method using monocytes
US7521195B1 (en) 2005-07-21 2009-04-21 Celera Corporation Lung disease targets and uses thereof
CA2619725C (en) 2005-08-18 2016-06-07 Ramot At Tel Aviv University Ltd. Single chain antibodies against beta-amyloid peptide
US8044179B2 (en) 2005-09-13 2011-10-25 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
CA2625403A1 (en) 2005-10-17 2007-04-26 Institute For System Biology Tissue-and serum-derived glycoproteins and methods of their use
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
RU2456298C2 (ru) 2005-12-20 2012-07-20 ЭсБиАй БАЙОТЕК КО., ЛТД. Антитело против ilt17
US8486412B2 (en) 2006-06-01 2013-07-16 Mayo Foundation For Medical Education And Research Immunity to folate receptors
CA2655933C (en) 2006-06-23 2014-09-09 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
US7910702B2 (en) 2006-07-28 2011-03-22 The Governors Of The University Of Alberta Recombinant antibodies to sclerotinia antigens
CA2660286A1 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
EP1900752A1 (en) 2006-09-15 2008-03-19 DOMPE' pha.r.ma s.p.a. Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
EP1900533A1 (de) 2006-09-16 2008-03-19 J. Zimmer Maschinenbau Gesellschaft m.b.H. Vorrichtung zum Auftragen von Substanz auf flächige Substrate
CA2665528C (en) 2006-10-12 2018-01-23 The University Of Tokyo Diagnosis and treatment of cancer using anti-ereg antibody
WO2008072723A1 (ja) 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. 抗Claudin3モノクローナル抗体およびそれを用いる癌の治療および診断
EP2121756A4 (en) 2006-12-20 2011-08-31 Mmrglobal Inc ANTIBODIES AND PROCESS FOR THEIR PREPARATION AND USE
US20080227704A1 (en) 2006-12-21 2008-09-18 Kamens Joanne S CXCL13 binding proteins
WO2008098788A2 (en) 2007-02-16 2008-08-21 Ktb Tumorforschungsgesellschaft Mbh Receptor and antigen targeted prodrug
WO2008101231A2 (en) 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
WO2008145136A1 (en) 2007-05-30 2008-12-04 Aarhus Universitet Stat3 inactivation by inhibition of the folate receptor pathway
JP5690589B2 (ja) 2007-06-25 2015-03-25 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 親水性スペーサーリンカーを含有する結合体
AU2008282863A1 (en) 2007-07-31 2009-02-05 Merck Sharp & Dohme Corp. IGF-1R specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
CN101139613B (zh) 2007-08-01 2011-06-08 姜荣锡 抗肿瘤二元多肽及其应用与制备方法
US20090087849A1 (en) * 2007-09-06 2009-04-02 Tripath Imaging, Inc. Nucleic acid-based methods and compositions for the detection of ovarian cancer
US20100330572A1 (en) 2007-12-21 2010-12-30 Assaraf Yehuda G Organic compounds
EP2241578B1 (en) 2008-01-11 2016-04-20 The University of Tokyo Anti-cldn6 antibody
WO2009132081A2 (en) 2008-04-24 2009-10-29 The Research Foundation Of State University Of New York Monoclonal antibody-based targeting of folate receptors
MY197840A (en) 2008-04-30 2023-07-20 Immunogen Inc Cross-linkers and their uses
RU2487877C2 (ru) 2008-04-30 2013-07-20 Иммьюноджен, Инк. Высокоэффективные конъюгаты и гидрофильные сшивающие агенты (линкеры)
US8383351B2 (en) 2008-06-11 2013-02-26 Oxford Brookes University Antibody to inhibin/ activin β-B subunit
ES3029483T3 (en) 2008-09-17 2025-06-24 Endocyte Inc Folate receptor binding conjugates of antifolates
US20100092470A1 (en) 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
WO2010058572A1 (en) 2008-11-20 2010-05-27 Oncotherapy Science, Inc. Methods for diagnosing or treating prostate cancer
CN101440130B (zh) 2008-11-21 2011-07-27 中国人民解放军第四军医大学 一种抗人IL-13Rα2单克隆抗体的重链和轻链的可变区
JP5923035B2 (ja) 2009-03-24 2016-05-24 バイオセプト インコーポレイティッド 細胞の捕捉および解析のデバイスおよび方法
CN102574915B (zh) * 2009-08-06 2014-10-22 伊缪纳斯制药株式会社 特异性结合Aβ寡聚体的抗体及其用途
JP6048660B2 (ja) 2009-09-21 2016-12-21 ランジュ ラルハン 甲状腺癌を診断および処置するための方法および組成物
US9175086B2 (en) 2010-02-10 2015-11-03 Immunogen, Inc. CD20 antibodies and uses thereof
MY171234A (en) * 2010-02-24 2019-10-04 Immunogen Inc Folate receptor 1 antibodies and immunoconjugates and uses thereof
EP3130605B1 (en) 2010-11-05 2020-01-08 Eisai Inc. Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers
MX2013011201A (es) * 2011-03-29 2013-12-16 Immunogen Inc Proceso para la elaboracion de conjugados de mejor homogeneidad.
SG193997A1 (en) * 2011-03-29 2013-11-29 Immunogen Inc Process for manufacturing conjugates of improved homogeneity
CN107537040A (zh) * 2011-03-29 2018-01-05 伊缪诺金公司 通过一步法制备类美登素抗体缀合物
UA125636C2 (uk) 2011-04-01 2022-05-11 Іммуноджен, Інк. Способи ідентифікації раку, який може реагувати на анти-folr1 антитіло або анти-folr1 імунокон'югат
WO2012138749A1 (en) 2011-04-04 2012-10-11 Immunogen, Inc. Methods for decreasing ocular toxicity of antibody drug conjugates
WO2012145112A2 (en) 2011-04-18 2012-10-26 Immunogen, Inc. Novel maytansinoid derivatives with sulfoxide linker
SI2731972T1 (en) 2011-07-15 2018-04-30 Eisai R&D Management Co., Ltd. Anti-folate receptor alpha antibodies and uses thereof
CA3137438A1 (en) 2012-08-31 2014-03-06 Immunogen, Inc. Diagnostic assays and kits for detection of folate receptor 1
WO2014055842A1 (en) 2012-10-04 2014-04-10 Immunogen, Inc. Process for preparing stable antibody maytansinoid conjugates
SG11201509043RA (en) 2013-05-14 2015-12-30 Immunogen Inc Anti-folr1 immunoconjugate dosing regimens
IL293871B1 (en) 2013-08-30 2025-10-01 Immunogen Inc Antibodies and assays for the detection of folate receptor 1
RU2696579C2 (ru) * 2013-10-08 2019-08-05 Иммьюноджен, Инк. Схемы применения иммуноконъюгата анти-folr1
US20150297744A1 (en) * 2014-03-28 2015-10-22 Immunogen, Inc. Anti-FOLR1 Immunoconjugate Dosing Regimens
CA2954051A1 (en) 2014-07-01 2016-01-07 Expression Pathology, Inc. Srm assays to chemotherapy targets
CN113842468B (zh) 2014-09-02 2025-08-29 伊缪诺金公司 用于配制抗体药物缀合物组合物的方法
CN116440279A (zh) 2015-09-17 2023-07-18 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
AU2018229277B2 (en) 2017-02-28 2025-03-20 Immunogen, Inc. Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof
CA3063893A1 (en) 2017-05-16 2018-11-22 Immunogen, Inc. Anti-folr1 immunoconjugates and anti-pd-1 antibody combinations

Also Published As

Publication number Publication date
US20140363453A1 (en) 2014-12-11
KR20190058696A (ko) 2019-05-29
CA3182262A1 (en) 2012-10-04
PT2694106T (pt) 2018-03-05
KR20240017965A (ko) 2024-02-08
AU2021206842B2 (en) 2024-12-19
AU2017202927B2 (en) 2019-01-17
AU2012236219A1 (en) 2013-10-10
CY1119960T1 (el) 2018-12-12
JP2018118997A (ja) 2018-08-02
TR201802659T4 (tr) 2018-03-21
IL273614A (en) 2020-05-31
MX2019010336A (es) 2019-10-14
EP4309671A3 (en) 2024-03-20
EP2694106B1 (en) 2017-12-13
JP2014513068A (ja) 2014-05-29
IL281714A (en) 2021-05-31
EA201791843A2 (ru) 2017-12-29
WO2012135675A2 (en) 2012-10-04
EA028805B1 (ru) 2018-01-31
EA201791843A3 (ru) 2018-05-31
IL281714B2 (en) 2023-11-01
US20250228960A1 (en) 2025-07-17
MX340640B (es) 2016-07-19
AU2017202927A1 (en) 2017-05-25
KR20210088746A (ko) 2021-07-14
US11135305B2 (en) 2021-10-05
KR102101160B1 (ko) 2020-04-16
AU2019202611B2 (en) 2021-05-06
NZ711375A (en) 2017-02-24
SI2694106T1 (en) 2018-04-30
NZ615742A (en) 2015-09-25
HK1254759A1 (en) 2019-07-26
IL228538B (en) 2018-12-31
KR101982317B1 (ko) 2019-05-27
EP3318273A1 (en) 2018-05-09
MX346555B (es) 2017-03-24
BR112013025415B1 (pt) 2021-03-16
AU2012236219B2 (en) 2017-02-23
ME03025B (me) 2018-10-20
DK2694106T3 (en) 2018-03-05
IL281714B1 (en) 2023-07-01
EA201391351A1 (ru) 2014-11-28
ZA202007440B (en) 2025-04-30
PL2694106T3 (pl) 2018-06-29
SMT201800103T1 (it) 2018-05-02
JP2024099612A (ja) 2024-07-25
JP2019194257A (ja) 2019-11-07
ES2661466T3 (es) 2018-04-02
JP2022062219A (ja) 2022-04-19
US20120282175A1 (en) 2012-11-08
EP4309671A2 (en) 2024-01-24
EP3318273B1 (en) 2019-08-21
EP2694106A2 (en) 2014-02-12
CA2831426C (en) 2023-02-21
RS56916B1 (sr) 2018-05-31
IL303208A (en) 2023-07-01
ES2965109T3 (es) 2024-04-11
UA125636C2 (uk) 2022-05-11
KR102489185B1 (ko) 2023-01-17
JP6018621B2 (ja) 2016-11-02
NO2893540T3 (es) 2018-06-09
AU2021206842A1 (en) 2021-08-12
CA2831426A1 (en) 2012-10-04
HUE036172T2 (hu) 2018-06-28
KR20140027969A (ko) 2014-03-07
IL228538A0 (en) 2013-12-31
US20180200383A1 (en) 2018-07-19
EP2694106A4 (en) 2015-04-08
CN108743965A (zh) 2018-11-06
JP2021006547A (ja) 2021-01-21
LT2694106T (lt) 2018-04-25
HRP20180358T1 (hr) 2018-04-06
JP2016147901A (ja) 2016-08-18
CN114441757A (zh) 2022-05-06
BR112013025415A2 (pt) 2016-12-27
US8709432B2 (en) 2014-04-29
KR20230013283A (ko) 2023-01-26
CN103747802A (zh) 2014-04-23
WO2012135675A3 (en) 2012-12-06
EP3636279A1 (en) 2020-04-15
KR20200039843A (ko) 2020-04-16
SG10201602553VA (en) 2016-05-30
EP3636279B1 (en) 2023-09-13
IL262956A (en) 2018-12-31
CN103747802B (zh) 2018-06-01
US20220143208A1 (en) 2022-05-12
MY186591A (en) 2021-07-29
AU2019202611A1 (en) 2019-05-02
MY180894A (en) 2020-12-11
IL262956B (en) 2020-04-30
SG193514A1 (en) 2013-10-30
UA113403C2 (xx) 2017-01-25

Similar Documents

Publication Publication Date Title
MX2013011098A (es) Metodos para aumentar la eficacia de la terapia contra el cancer con receptor 1 de folato (folr1).
ECSP24031979A (es) Compuestos terapéuticamente activos y sus métodos de uso
CY1120929T1 (el) Λιπιδια για συστασεις διανομης θεραπευτικου παραγοντα
CL2018000353A1 (es) Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes
ECSP14014544A (es) Compuestos terapéuticamente activos y sus métodos de uso
CY1120374T1 (el) Ενεργοποιητες κινασων πυρουβικου για χρηση σε θεραπεια
MX2021003858A (es) Conjugados para el tratamiento de enfermedades causadas por celulas que expresan psma.
AR091837A1 (es) Compuestos para inmunoterapia dirigida
ECSP14012726A (es) Compuestos terapéuticamente activos y sus métodos de uso
MX387487B (es) Compuestos polifluorados que actúan como inhibidores de la tirosina cinasa de bruton.
MX2014000292A (es) Usos de inhibidores etiquetados hsp90.
CR20150571A (es) Compuestos y composiciones terapéuticos
CR20120522A (es) Pirrolobenzodiacepinas y conjugados de las mismas
NI201300041A (es) Antagonistas de mdm2 de espiro-oxindol
AR082340A1 (es) Metodos y composiciones para la terapia del cancer de higado
MX2017006167A (es) Compuestos que interactúan con glicanos y métodos de uso.
UY34165A (es) ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?.
PE20150360A1 (es) Agentes de union de proteina de r-espondina humana (rsp03) y usos de los mismos
SV2019005822A (es) Metodos para tratar el cáncer de próstata
CR20150390A (es) Inhibidores de la yodoproteina basada en 2,3-dihidroimidazol[1,2-c]pirimidin-5(1-h)-ona-asociada a la fosfolipasa a2 (lp-pla2)
CL2015002531A1 (es) Anticuerpos contra quimiocinas cxc pan-elr+
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.
CR20130488A (es) Derivados de tieno [2,3-d]pirimidina y su uso para tratar arritmia
CO6880061A2 (es) Método para tratar el cáncer mediante el uso combinado de fármacos
BR112014031556A2 (pt) derivados de bendamustina e compostos relacionados, e uso médico dos mesmos na terapia do câncer

Legal Events

Date Code Title Description
FG Grant or registration